Sight Sciences reports Q2 EPS (25c), consensus (30c)
PremiumThe FlySight Sciences reports Q2 EPS (25c), consensus (30c)
2M ago
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
Premium
Press Releases
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
2M ago
Sight Sciences price target raised to $6.50 from $5.40 at Morgan Stanley
Premium
The Fly
Sight Sciences price target raised to $6.50 from $5.40 at Morgan Stanley
2M ago
Sight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms
PremiumThe FlySight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms
4M ago
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Premium
Press Releases
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
4M ago
Sight Sciences announces publication of analysis from ROMEO study
Premium
The Fly
Sight Sciences announces publication of analysis from ROMEO study
4M ago
Sight Sciences Enhances Transparency with Strategic Financial Moves
PremiumCompany AnnouncementsSight Sciences Enhances Transparency with Strategic Financial Moves
5M ago
Sight Sciences announces $34M patent infringement verdict against Alcon
Premium
The Fly
Sight Sciences announces $34M patent infringement verdict against Alcon
5M ago
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
Premium
Press Releases
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100